SCHEMBL29327713

SCHEMBL29327713

CCc1ccc(-c2nc3ccc(NC(=O)c4cc(C#N)ccc4S(=O)(=O)C(F)(F)F)cc3o2)cc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 7/20 0.63
▸ TP53 P04637 3/20 0.48
▸ MAPT P10636 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CETP P11597 7/20 0.47
▸ POLB P06746 1/20 0.46
▸ CEPT1 Q9Y6K0 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ CYP2C8 P10632 2/20 0.45
▸ NR1I2 O75469 1/20 0.45
▸ PPARD Q03181 1/20 0.45
▸ PPARA Q07869 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327683 0.94 PPARG (0.72) PPARGTP53MAPTSMN1; SMN2CETP
SCHEMBL29327605 0.92 PPARG (0.67) PPARGTP53MAPTSMN1; SMN2CETP
SCHEMBL29327933 0.86 PPARG (0.55) PPARGTP53MAPTSMN1; SMN2CETP
SCHEMBL29327936 0.85 PPARG (0.60) PPARGTP53MAPTSMN1; SMN2CETP
SCHEMBL29327587 0.85 PPARG (0.77) PPARGTP53MAPTSMN1; SMN2CETP
SCHEMBL29327677 0.85 PPARG (0.59) PPARGTP53MAPTSMN1; SMN2CETP
SCHEMBL29327928 0.83 APP (0.48) PPARGTP53MAPTSMN1; SMN2THRB
SCHEMBL29327709 0.83 PPARG (0.58) PPARGTP53MAPTSMN1; SMN2CETP
SCHEMBL29327715 0.82 PPARG (0.47) PPARGTP53MAPTSMN1; SMN2THRB
SCHEMBL29327844 0.82 PPARG (0.60) PPARGTP53MAPTSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PPARG 1/4885TP53 1398/4885MAPT 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback